demonstrated that abnormal glycosylation of MUC1 in colon cancer, particularly the exposure of Tn and TF antigens, may promote tumor immune evasion through binding with MGL expressed on DCs and macrophages; additionally, MUC1’s correlation with the adverse prognostic marker Helix pomatia agglutinin (HPA) indicates significant interactions between MUC1 and immune regulatory factors (107). This evidence concerns the gene MUC1 and neoplasm.